Harrow (HROW) Q2 2026 earnings review
Revenue Rebounds, But a Massive H2 Execution Mountain Looms
Harrow's Q2 2026 results show a 60% sequential revenue rebound to $70.7 million, shaking off Q1's gross-to-net modeling disaster. However, profitability is severely lagging. Net Income fell to negative $17.3 million as SG&A expenses surged 60% YoY to fuel a massive commercial sales force expansion. Management reiterated its aggressive full-year guidance ($350-$365M Revenue, $80-$100M Adj. EBITDA), which implies an astronomical ramp in the second half of the year. The table is set with new payer coverage, normalized inventories, and an expanded sales team, but the company is now completely reliant on flawless H2 execution.
🐂 Bull Case
VEVYE delivered record revenue of $29.4 million (+58% YoY) and expanded its market share to 14.6%. A major new commercial pharmacy benefit manager contract effective August 1 should further accelerate volume and improve the gross-to-net ratio.
Despite losing ASC pass-through reimbursement on April 1, IHEEZO unit demand grew 44% sequentially. The pivot to in-office procedures is working, and a ~25% net price improvement took effect July 1.
🐻 Bear Case
To hit the midpoint of FY26 guidance, Harrow must generate ~$242 million in revenue and ~$104 million in Adjusted EBITDA in H2. Any delay in sales force productivity or new product launches will result in a massive miss.
Gross margins decayed from 75% to 71% YoY, while SG&A exploded to $53.3 million. The company is burning cash (-$18.7M operating cash flow in H1) to fund its commercial bets before the revenue fully materializes.
⚖️ Verdict: ⚪
Neutral. The underlying prescription demand for VEVYE and IHEEZO is genuinely accelerating, and the TYRVAYA acquisition is strategically sound. However, the sheer math required to hit FY26 guidance demands perfection, making the stock highly vulnerable to any operational hiccups in Q3.
Key Themes
VEVYE Commercial Momentum
Accelerating. VEVYE is definitively proving its demand elasticity. Revenue jumped to $29.4 million (+40% QoQ) and total prescriptions grew 21% sequentially, outpacing the broader branded dry eye market's 14% growth. Management successfully replaced the costly $0 first-fill program with traditional physician sampling, and the August 1 coverage win with a top-three PBM acts as a massive H2 catalyst.
TYRVAYA Acquisition Broadens Dry Eye Dominance
The acquisition of TYRVAYA from Viatris is a highly synergistic move. It gives Harrow's newly doubled sales force a complementary product (zero contraindications, no ocular adverse events) to cross-sell alongside VEVYE. Crucially, it was funded from cash on hand with no dilution, and is expected to contribute >$30 million in revenue by 2027.
The ImprimisRx Laggard
Decelerating. While branded revenue surged 33% YoY, the legacy ImprimisRx (compounding) business dropped 32% YoY ($14.6M vs $21.5M). Management attributes this to a deliberate shift of Klarity-C patients to VEVYE, inventory shortfalls, and a strategic exit from the California market. Even if intentional, this segment is actively dragging down top-line growth and requires stabilization by year-end as promised.
Navigating the ASC Macro Shift with IHEEZO
Accelerating. The loss of ASC pass-through reimbursement on April 1 was a major macro/regulatory threat to IHEEZO. However, the product posted its highest unit volume quarter ever (65,477 units, +44% QoQ). The aggressive pivot to in-office retina procedures is working. Coupled with a 25% net price improvement effective July 1, IHEEZO is positioned as a primary profit engine for H2.
Runaway SG&A and Margin Compression
Reversing. Harrow's operating leverage has completely inverted in the short term. Gross margin fell to 71% (down from 75% YoY) due to fixed cost amortization and product mix. Meanwhile, SG&A surged by $20 million YoY to $53.3 million. Harrow has built a massive fixed-cost commercial machine; if the H2 revenue ramp stalls, the cash burn will become an immediate crisis.
Other KPIs
Accelerating. Up 39% sequentially and 162% YoY. May 2026 was the strongest month in the product's history. With the surgical sales force now tripled, this product is moving from a turnaround story to a core growth pillar.
Stable. Up from $72.9 million at year-end 2025. Despite burning $18.7 million in operating cash flow in H1 2026, Harrow generated positive cash via financing activities ($48.4M) to maintain a healthy balance sheet ahead of the TYRVAYA cash integration.
Guidance
Accelerating. Management firmly reiterated this target. With H1 actual revenue at $114.9 million, achieving the $357.5 million midpoint requires an astonishing $242.6 million in H2. This implies H2 must be more than double H1.
Reversing. Reaching the $90 million midpoint requires generating roughly $104 million in Adjusted EBITDA in H2, effectively reversing the -$13.9 million burn experienced in H1. Management believes the pricing improvements for VEVYE and IHEEZO, combined with normalized channel inventories, will allow incremental revenue to fall directly to the bottom line.
Key Questions
TYRVAYA Cannibalization Risk
With the integration of TYRVAYA, how will the sales force be incentivized to ensure TYRVAYA acts as an accretive cross-sell rather than cannibalizing VEVYE's hard-won market share?
VEVYE Gross-to-Net Stability
After Q1's $8M revenue reduction due to gross-to-net modeling errors, you noted business rules were adjusted. Can you quantify the exact sequential improvement in ASP achieved in Q2 to prove these guardrails are holding?
ImprimisRx Floor
ImprimisRx revenue fell 32% YoY. While the Klarity-C transition and California exit explain part of this, at what specific quarterly revenue run-rate do you expect this segment to finally base out and return to growth?